Search results for " hepatitis B"
showing 10 items of 52 documents
Influence of universal HBV vaccination on chronic HBV infection in Italy: Results of a cross-sectional multicenter study
2017
Background and Aim The universal hepatitis B vaccination for infants and 12-year-old adolescents (the latter limited to the first 12 years of application) was launched in Italy in 1991. Twenty-three years later we evaluated the impact of the vaccination campaign on the burden of HBsAg-positive chronic liver diseases (CLD). Material and Methods 513 HBsAg-positive chronic carriers referring to 16 Italian liver units were investigated and compared with HBsAg carriers enrolled in previous surveys. Results The proportion of inactive carriers decreased from 20.0% in 2001 to 3.3% in 2014, while that of cirrhotic patients increased from 22.6 to 33.2%. Regarding the age class 0–33 (fully covered by …
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir
2019
Background and Aims: Tenofovir disoproxil fumarate (TDF) is recommended for chronic hepatitis B (CHB) treatment, but it may induce kidney dysfunction whose management is not yet known. This Italian, multicentre, retrospective study aimed to assess the efficacy and safety of switching to entecavir (ETV) patients who developed TDF-associated glomerular and/or tubular dysfunction. Methods: A total of 103 TDF-treated patients were included as follows: age 64 years, 83% male, 49% cirrhotics, 98% with undetectable HBV DNA, 47% with previous lamivudine resistance (LMV-R) and 71% previously treated with adefovir. Twenty-nine (28%) were switched to ETV because estimated glomerular filtration rate (e…
Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?
2017
International audience
Ten millennia of hepatitis B virus evolution
2021
Hepatitis B virus (HBV) has been infecting humans for millennia and remains a global health problem, but its past diversity and dispersal routes are largely unknown. We generated HBV genomic data from 137 Eurasians and Native Americans dated between ~10,500 and ~400 years ago. We date the most recent common ancestor of all HBV lineages to between ~20,000 and 12,000 years ago, with the virus present in European and South American hunter-gatherers during the early Holocene. After the European Neolithic transition, Mesolithic HBV strains were replaced by a lineage likely disseminated by early farmers that prevailed throughout western Eurasia for ~4000 years, declining around the end of the 2nd…
Correlation between the single nucleotide polymorphism (SNP) rs4374383 in MERTK gene with the risk of development and progression of liver disease
High performance of intravoxel incoherent motion diffusion MRI in detecting viral hepatitis-b induced liver fibrosis.
2019
Background: Recently a small cohort study demonstrated that intravoxel incoherent motion (IVIM) diffusion MRI can detect early stage liver fibrosis. Using modified IVIM data acquisition parameters, the current study aims to confirm this finding. Methods: Twenty-six healthy volunteers, three patients of chronic viral hepatitis-b but without fibrosis and one mild liver steatosis subject, and 12 viral hepatitis-b patients with fibrosis (stage 1–2=7, stage 3–4=5) were included in this study. With a 1.5-T MR scanner and respiration-gating, IVIM diffusion imaging was acquired using a single-shot echo-planar sequence with a b -value series of 2, 0, 1, 15, 20, 30, 45, 50, 60, 80, 100, 200, 300, 600…
Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis.
2006
To the Editor: Tang et al.1 recently reported that lamivudine (LAM) improves renal outcome in patients with chronic hepatitis B virus (HBV) infection and membranous nephropathy. We would like to add our experience on acute hepatitis B and rapidly progressive glomerulonephritis.
Risk of Virus Contamination Through Surgical Smoke During Minimally Invasive Surgery: A Systematic Review of the Literature on a Neglected Issue Revi…
2020
Abstract Context The coronavirus disease 2019 (COVID-19) pandemic raised concerns about the safety of laparoscopy due to the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diffusion in surgical smoke. Although no case of SARS-CoV-2 contagion related to surgical smoke has been reported, several international surgical societies recommended caution or even discouraged the use of a laparoscopic approach. Objective To evaluate the risk of virus spread due to surgical smoke during surgical procedures. Evidence acquisition We searched PubMed and Scopus for eligible studies, including clinical and preclinical studies assessing the presence of any virus in the surgical smoke fr…
Diversity of Pharmacological Properties in Chinese and European Medicinal Plants: Cytotoxicity, Antiviral and Antitrypanosomal Screening of 82 Herbal…
2011
In an extensive screening, the antiviral, antitrypanosomal and anticancer properties of extracts from 82 plants used in traditional Chinese medicine and European phytomedicine were determined. Several promising plants that were highly effective against hepatitis B virus (HBV), bovine viral diarrhoea virus (BVDV)—a flavivirus used here as a surrogate in vitro model of hepatitis C virus, trypanosomes (Trypanosoma brucei brucei) and several cancer cell lines were identified. Six aqueous extracts from Celosia cristata, Ophioglossum vulgatum, Houttuynia cordata, Selaginella tamariscina, Alpinia galanga and Alpinia oxyphylla showed significant antiviral effects against BVDV without toxic effects …
Imūnā atbildes reakcija uz vakcināciju pret vīrushepatītu B hemodialīzes pacientiem
2018
Pamatojums: Hemodialīzes (HD) pacientiem ir paaugstināts ar asinīm pārnesamām infekciju risks, piemēram, vīrushepatīta B infekcija (HBV). Pacientiem ar terminālu nieru mazspēju bieži ir imūnsistēmas nomākums, kas rezultējās ar nepietiekamu imūnās atbildes reakciju pret HBV vakcināciju. Adekvāta imunoloģiska atbilde it tad, ja anti-HBs-antivielu titrs >10 mSV/ml. Lai gan atbildes reakcija vispārējā populācijā ir aptuveni 95%, HD pacientiem tā ir robežās no 50-80%. Mērķis: noteikt HBV infekcijas izplatību, identificēt imūno atbildes reakciju HD pacientiem uz HBV vakcināciju un izvērtēt tās ietekmējošus klīniskus un laboratoriskus faktorus. Materiāli un metodes: Tika analizēta HBV izplatība HD…